Create Medic Co., Ltd.
Fiscal Year Ending December 2026 Q2 Interim Financial Results [Japanese GAAP] (Consolidated)
For the six months ended December 2026, consolidated net sales were 6,932 million yen (up 5.6% YoY), operating income 336 million yen (△38.6%), ordinary income 398 million yen (△24.2%), and net income attributable to owners of the parent 260 million yen (△37.0% YoY), with a decline in profitability despite growth in in-house sales. While product sales increased, rising costs and overseas market development expenses pressured profits. The year-end dividend forecast remains unchanged, and the full-year earnings forecast has already been revised in the press release.
Key Figures
- Sales: 6,932百万円 (YoY +5.6%)
- Operating income: 336百万円 (YoY △38.6%)
- Net income attributable to owners of the parent (interim): 260百万円 (YoY △37.0%)
AI要約
Overview of results
Although in-house sales grew steadily, profits were significantly reduced due to higher cost of sales and increased overseas market development expenses. New products in the urology segment contributed to sales, but currency effects and elevated raw material prices squeezed profits. Net sales rose 5.6% year over year to 6,932 million yen, operating income declined 38.6% to 336 million yen, and net income attributable to owners of the parent fell 37.0% to 260 million yen.
Outlook and financial position
Full-year earnings guidance has been revised, see the notice titled ‘Difference between the second-quarter (interim) earnings forecast and actual results and revision of the full-year consolidated earnings forecast.’ The timing of the dividend payment and the expected year-end dividend remain unchanged, but there is no change to the latest dividend forecast. Cash and cash equivalents at year-end were 4,936百万円, and attention should be paid to shareholder equity movements including treasury stock acquisitions.
Create Medic Co., Ltd.
Company overview · Stock price · Financial data · All IR
